AstraZeneca

AstraZeneca, a British-Swedish pharmaceutical giant, is currently newsworthy due to its significant investment in China and legal issues involving a former executive. The company plans to invest $15 billion in China by 2030, expanding manufacturing and R&D. This commitment coincides with UK Prime Minister Keir Starmer's visit to China, signaling strengthened Sino-UK commercial ties. However, AstraZeneca's former China head has been formally charged with medical insurance fraud, illegal trading, and unlawful collection of personal information, casting a shadow over its expansion. Meanwhile, CEO Pascal Soriot received a 6.4% pay rise, bringing his total remuneration to £17.7m. Experts have also warned about a shrinking pipeline of new drugs to fight superbugs, with projects from large pharma companies, including AstraZeneca, declining by 35% in the last five years. This highlights concerns about the future of antimicrobial drug development and its potential impact on global health.